Pharmaceutical

Codagenix pursues RSV vaccine development amid unexpected challenges

Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.

Aug 30, 2023 - 20:00
Codagenix pursues RSV vaccine development amid unexpected challenges
Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.
Read the original article

Tags:

Previous Article

FDA shuns Outlook Therapeutics with wet AMD drug BLA rejection

Next Article

Roche wins first approval for subcutaneous Tecentriq

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Agomab wins FDA orphan drug status for idiopathic pulmonary fibrosis asset

Agomab wins FDA orphan drug status for idiopathic pulmo...

Jun 8, 2024

ESMO 2023: Mirati’s Krazati and immuno-oncology combo to shape first-line NSCLC

ESMO 2023: Mirati’s Krazati and immuno-oncology combo t...

Oct 23, 2023

Beacon secures $170m to advance ophthalmic gene therapies

Beacon secures $170m to advance ophthalmic gene therapies

Jul 4, 2024